Table 2:
Total Admissions for all patients | With ILD | Without ILD | |||
---|---|---|---|---|---|
Reasons for Hospitalization | Total Admissions* | Elective Admissions | LOS, days (mean) | Total Admissions* | Total Admissions* |
All Scleroderma related | 382 | 125 | 5.5 (6.4) | 231 | 151 |
Digital Vasculopathy | 100 | 77 | 4.3 (2.4) | 39 | 61 |
Intravenous Prostacyclin (epoprostenol) | 100 | 77 | 4.3 (2.4) | 39 | 61 |
Gastroenterology | 91 | 0 | 5.2 (6.3) | 49 | 42 |
GI dysmotility-upper | 21 | 0 | 3.9 (2.7) | 5 | 16 |
GI bleed | 23 | 0 | 3.2 (2.9) | 15 | 8 |
Gastritis/Ulcer | 23 | 0 | 3.8 (2.7) | 18 | 5 |
GI Dysmotility – Lower | 21 | 0 | 10.5(10.8) | 9 | 12 |
Small Intestinal Bowel Overgrowth | 3 | 0 | 4.7(3.1) | 2 | 1 |
Cardiovascular | 54 | 5 | 4.1(3.5) | 40 | 14 |
Pericarditis/ Pericardial Effusion | 8 | 0 | 5.4(3.9) | 6 | 2 |
Arrythmias | 30 | 5 | 3.4(3.3) | 20 | 10 |
Systolic Heart Failure | 9 | 0 | 5.0(4.6) | 9 | 0 |
Diastolic Heart Failure | 7 | 0 | 4.3 (2.0) | 5 | 2 |
Cardiopulmonary | 46 | 2 | 7.0 (7.4) | 28 | 18 |
Pulmonary Hypertension | 46 | 2 | 7.0 (7.4) | 28 | 18 |
Treatment/Infusion-related | 37 | 36 | 5.4 (7.6) | 34 | 3 |
Rituximab/Cyclophosphamide Infusions | 31 | 30 | 2.2 (1.5) | 28 | 3 |
Stem Cell Transplant | 6 | 6 | 21.8 (3.9) | 6 | 0 |
Renal | 25 | 5 | 9.9 (11.9) | 19 | 6 |
Scleroderma Renal Crisis | 11 | 0 | 15.6 (15.7) | 9 | 2 |
HTN Urgency | 4 | 0 | 6.8 (7.7) | 3 | 1 |
HTN Emergency | 5 | 0 | 6.8 (4.1) | 3 | 2 |
Renal Transplant/ Rejection | 5 | 5 | 3.0 (1.2) | 4 | 1 |
Pulmonary Involvement | 19 | 0 | 7.4 (9.7) | 18 | 1 |
Aspiration Pneumonitis | 7 | 0 | 9.0 (12.9) | 6 | 1 |
Interstitial Lung Disease | 12 | 0 | 6.5 (7.8) | 12 | 0 |
Malnutrition/Failure to Thrive | 7 | 0 | 5.0 (2.4) | 4 | 3 |
Musculoskeletal | 3 | 0 | 5.3 (3.2) | 0 | 3 |
Myositis/Myonecrosis | 3 | 0 | 5.3 (3.2) | 0 | 3 |
Abbreviations: GI=gastrointestinal; HTN=Hypertension; LOS=length of Stay;
Total Admissions refers to all elective and emergent or urgent admissions.